Clinical Policy: Elbasvir/grazoprevir (Zepatier) Reference Number: ERX.SPMN.181 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Policy/Criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions® that elbasvir/grazoprevir (Zepatier™) is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Chronic Hepatitis C Infection (must meet all): 1. Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist; 2. Age ≥ 18 years; 3. Diagnosis of chronic hepatitis C virus (HCV) infection as evidenced by detectable HCV RNA levels over a six-month period; 4. Confirmed HCV genotype is 1 or 4; 5. Life expectancy ≥ 12 months with HCV treatment; 6. Documented sobriety from alcohol and illicit IV drugs for ≥ 6 months prior to starting therapy, if applicable; 7. Advanced liver disease defined as a or b: a. Significant fibrosis indicated by i or ii: i. Liver biopsy showing a METAVIR score of F2 or equivalent (Knodell, Scheuer, Batts-Ludwig – F2; Ishak – F3/4); ii. One serologic test and one radiologic test showing an equivalent score to METAVIR F2 per Appendix B; b. Cirrhosis indicated by i, ii, or iii: i. Hepatocellular carcinoma (HCC) - and the HCC is amenable to resection, ablation, or transplant; ii. Liver biopsy showing a METAVIR score of F4 or equivalent (Knodell, Scheuer, Batts-Ludwig – F4; Ishak - F5/6); iii. Both of the following: a) One serologic test showing an equivalent score to METAVIR F4 per Appendix B; b) One radiologic test showing an equivalent score to METAVIR F4 per Appendix B or other radiologic test showing evidence of cirrhosis (e.g., portal hypertension); 8. Prescribed regimen is consistent with an FDA or AASLD-IDSA recommended regimen (see Appendix D and E for reference); 9. Member has contraindication or intolerance to Harvoni and Sovaldi (Harvoni is the preferred agent; Sovaldi in combination with ribavirin and/or peg-interferon should be used if Harvoni is contraindicated). Page 1 of 6 CLINICAL POLICY Elbasvir/grazoprevir Approval duration: 8 weeks B. Other diagnoses/indications: Refer to ERX.SPMN.16 - Global Biopharm Policy. II. Continued Approval A. Chronic Hepatitis C Infection (must meet all): 1. Currently receiving medication via health plan benefit or member has previously met all initial approval criteria; 2. HCV RNA is not present or, if present, has not increased by > 10-fold (>1 log10 IU/mL); 3. Pharmacy claims support adherence to therapy. Approval duration: up to a total of 16 weeks* (*Approved duration should be consistent with a regimen in Appendix D or E) B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy; or 2. Refer to ERX.SPMN.16 - Global Biopharm Policy. Background Description/Mechanism of Action: Zepatier is a fixed-dose combination tablet containing elbasvir and grazoprevir for oral administration. Elbasvir is an HCV NS5A inhibitor, and grazoprevir is an HCV NS3/4A protease inhibitor. Each tablet contains 50 mg elbasvir and 100 mg grazoprevir. Zepatier Formulations Tablet, Oral: Zepatier: 50 mg elbasvir and 100 mg grazoprevir Ribavirin Formulations: Capsule, Oral: Rebetol: 200 mg Ribasphere: 200 mg Generic: 200 mg Solution, Oral: Rebetol: 40 mg/mL (100 mL) Tablet, Oral: Copegus: 200 mg Moderiba (includes dose packs): 200 mg, 400 mg, 600 mg Ribasphere: 200 mg, 400 mg, 600 mg Ribasphere RibaPak (dose packs): 200 mg, 400 mg, 600 mg Generic: 200 mg Page 2 of 6 CLINICAL POLICY Elbasvir/grazoprevir FDA Approved Indications: Zepatier is a fixed-dose combination oral tablet formulation / NS5A inhibitor/NS3/4A protease inhibitor indicated with or without ribavirin for: Treatment of chronic HCV genotypes 1 or 4 infection in adults. Appendices Appendix A: Abbreviation Key APRI: AST to platelet ratio IDSA: Infectious Diseases Society of AASLD: American Association for the America Study of Liver Diseases MRE: magnetic resonance elastography CTP: Child Turcotte Pugh NS3/4A, NS5A/B: nonstructural protein DAA: direct acting antiviral Peg-IFN: pegylated interferon FIB-4: Fibrosis-4 index PI: protease inhibitor HCC: hepatocellular carcinoma RBV: ribavirin HCV: hepatitis C virus Appendix B: Approximate Scoring Equivalencies using METAVIR F2/F4 as Reference Fibrosis/ Serologic Tests* Radiologic Tests† Liver Biopsy‡ Cirrhosis Fibro FIBRO APRI FIB-4 FibroScan MRE METAVIR Ishak Test Spect II (kPa) (kPa) Significant ≥0.48 ≥42 >0.7 >3.25 ≥7.5 ≥3.20 F2 F3-4 fibrosis Cirrhosis ≥0.75 ≥42 >1.5 >3.25 ≥12.0 ≥4.71 F4 F5-6 *Serologic tests: FibroTest (available through Quest as FibroTest or LabCorp as FibroSure) FIBROSpect II (available through Prometheus Laboratory) APRI (AST to platelet ratio index) FIB-4 (Fibrosis-4 index: includes age, AST level, platelet count) †Radiologic tests: FibroScan (ultrasound-based elastography) MRE (magnetic resonance elastography) ‡Liver biopsy (histologic scoring systems): METAVIR F2/F4 is equivalent to Knodell, Scheuer, and Batts-Ludwig F2/F4 and Ishak F3-4/F5- 6 METAVIR fibrosis stages: F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = few septa; F3 = numerous septa without cirrhosis; F4 = cirrhosis Appendix C: Direct-Acting Antivirals (DAAs) for Treatment of HCV Infection Brand Drug Class Name NS5A Nucleotide Non-Nucleoside NS3/4A CYP3A Inhibitor Analog NS5B NS5B Palm Protease Inhibitor Polymerase Polymerase Inhibitor Inhibitor Inhibitor (PI)** Daklinza Daclatasvir Epclusa* Velpatasvir Sofosbuvir Harvoni* Ledipasvir Sofosbuvir Olysio Simeprevir Page 3 of 6 CLINICAL POLICY Elbasvir/grazoprevir Brand Drug Class Name NS5A Nucleotide Non-Nucleoside NS3/4A CYP3A Inhibitor Analog NS5B NS5B Palm Protease Inhibitor Polymerase Polymerase Inhibitor Inhibitor Inhibitor (PI)** Sovaldi Sofosbuvir Technivie* Ombitasvir Paritaprevir Ritonavir Viekira Ombitasvir Dasabuvir Paritaprevir Ritonavir XR/PAK* Zepatier* Elbasvir Grazoprevir *Combination drugs **Additional PIs no longer recommended: Victrelis (boceprevir), Incivek (telaprevir) Appendix D: FDA-Approved Regimens and Treatment Durations Treatment Genotype Failed Treatment Recommended Regimen Naive/Experienced Regimen See footnotes for duration No Cirrhosis or Compensated Cirrhosis (CTP/Child-Pugh Class A) Treatment naive 1a None Zepatier§ If no baseline NS5A polymorphisms. Zepatier + RBV○ If baseline NS5A polymorphisms. 1b, 4 None Zepatier§ Treatment experienced 1a Peg-IFN/RBV Zepatier§ If no baseline NS5A polymorphisms. Zepatier + RBV○ If baseline NS5A polymorphisms. 1a, 1b NS3/Peg-IFN/RBV** Zepatier + RBV§ 1b Peg-IFN/RBV Zepatier§ 4 Peg-IFN/RBV Zepatier + RBV○ **NS3 includes Victrelis (boceprevir), Incivek (telaprevir) or Olysio (simeprevir) §Treatment duration - 12 weeks ○Treatment duration – 16 weeks Appendix E: AASLD-IDSA Recommended Regimens and Treatment Durations Treatment Genotype Failed Treatment Recommended Regimen Naive/Experienced Regimen See footnotes for duration No Cirrhosis or Compensated Cirrhosis (CTP/Child-Pugh Class A) Treatment naive 1a None Zepatier§ If no baseline NS5A polymorphisms. Zepatier○ If baseline NS5A polymorphisms. 1b, 4 None Zepatier§ Treatment 1* NS3 PI/Peg-IFN/RBV** Zepatier + RBV○ experienced If baseline NS5A polymorphisms. Zepatier + RBV§ 1a Peg-IFN/RBV Zepatier + RBV○ If baseline NS5A polymorphisms. Page 4 of 6 CLINICAL POLICY Elbasvir/grazoprevir Treatment Genotype Failed Treatment Recommended Regimen Naive/Experienced Regimen See footnotes for duration Zepatier + RBV§ If no baseline NS5A polymorphisms. 1b, 4 Peg-IFN/RBV Zepatier + RBV§ 4 Peg-IFN/RBV Zepatier + RBV○ *Subtype a or b, or unknown subtype **NS3 includes Victrelis (boceprevir), Incivek (telaprevir) or Olysio (simeprevir) §Treatment duration - 12 weeks ○Treatment duration – 16 weeks Coding Implications Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. HCPCS Description Codes Reviews, Revisions, and Approvals Date Approval Date Policy created. 08/1 09/16 6 References 1. Zepatier Prescribing Information. Whitehouse Station, NJ: Merck and Company, Inc.; January 2016. Available at http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed August 2, 2016. 2. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed July 12, 2016. 3. Curry MP, Nezam AH. Noninvasive assessment of hepatic fibrosis: Overview of serologic and radiographic tests. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at UpToDate.com. Accessed July 15, 2016. 4. Fiel MI. Histologic scoring system for chronic liver disease. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at UpToDate.com. Accessed July 15, 2016. 5. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014; 16(372): 1-7. DOI 10.1007/s11894-014-0372-6. 6. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (Fibrotest–Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: The Fibropaca study. Am J Gastroenterol. 2006; 101: 547-555. DOI: 10.1111/j.1572-0241.2006.0411.x